173 related articles for article (PubMed ID: 32145228)
1. Development of dextrin-amphotericin B formulations for the treatment of Leishmaniasis.
Silva-Carvalho R; Fidalgo J; Melo KR; Queiroz MF; Leal S; Rocha HA; Cruz T; Parpot P; Tomás AM; Gama M
Int J Biol Macromol; 2020 Jun; 153():276-288. PubMed ID: 32145228
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid-amphotericin B nanocomplexes: a promising anti-leishmanial drug delivery system.
Silva-Carvalho R; Leão T; Bourbon AI; Gonçalves C; Pastrana LM; Parpot P; Amorim I; Tomás AM; Gama FM
Biomater Sci; 2022 Apr; 10(8):1952-1967. PubMed ID: 35253814
[TBL] [Abstract][Full Text] [Related]
3. Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis.
Singh PK; Pawar VK; Jaiswal AK; Singh Y; Srikanth CH; Chaurasia M; Bora HK; Raval K; Meher JG; Gayen JR; Dube A; Chourasia MK
Int J Biol Macromol; 2017 Dec; 105(Pt 1):1220-1231. PubMed ID: 28780414
[TBL] [Abstract][Full Text] [Related]
4. Nanoemulsions loaded with amphotericin B: a new approach for the treatment of leishmaniasis.
Caldeira LR; Fernandes FR; Costa DF; Frézard F; Afonso LC; Ferreira LA
Eur J Pharm Sci; 2015 Apr; 70():125-31. PubMed ID: 25660615
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity.
Kumar P; Shivam P; Mandal S; Prasanna P; Kumar S; Prasad SR; Kumar A; Das P; Ali V; Singh SK; Mandal D
Int J Nanomedicine; 2019; 14():6073-6101. PubMed ID: 31686803
[TBL] [Abstract][Full Text] [Related]
6. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis.
Sánchez-Brunete JA; Dea MA; Rama S; Bolás F; Alunda JM; Torrado-Santiago S; Torrado JJ
J Drug Target; 2004; 12(7):453-60. PubMed ID: 15621670
[TBL] [Abstract][Full Text] [Related]
8. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis.
Chattopadhyay A; Jafurulla M
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):7-12. PubMed ID: 22100811
[TBL] [Abstract][Full Text] [Related]
9. Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation.
Gupta PK; Jaiswal AK; Kumar V; Verma A; Dwivedi P; Dube A; Mishra PR
Mol Pharm; 2014 Mar; 11(3):951-63. PubMed ID: 24495144
[TBL] [Abstract][Full Text] [Related]
10. Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex.
Mohamed-Ahmed AH; Seifert K; Yardley V; Burrell-Saward H; Brocchini S; Croft SL
Antimicrob Agents Chemother; 2013 Oct; 57(10):4608-14. PubMed ID: 23796924
[TBL] [Abstract][Full Text] [Related]
11. Optimizing efficacy of amphotericin B through nanomodification.
Vyas SP; Gupta S
Int J Nanomedicine; 2006; 1(4):417-32. PubMed ID: 17722276
[TBL] [Abstract][Full Text] [Related]
12. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
[TBL] [Abstract][Full Text] [Related]
13. Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies.
Mudavath SL; Talat M; Rai M; Srivastava ON; Sundar S
Drug Des Devel Ther; 2014; 8():1235-47. PubMed ID: 25214767
[TBL] [Abstract][Full Text] [Related]
14. Enhancing Safety and Efficacy by Altering the Toxic Aggregated State of Amphotericin B in Lipidic Nanoformulations.
Das S; Devarajan PV
Mol Pharm; 2020 Jun; 17(6):2186-2195. PubMed ID: 32324420
[TBL] [Abstract][Full Text] [Related]
15. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum.
Ordóñez-Gutiérrez L; Espada-Fernández R; Dea-Ayuela MA; Torrado JJ; Bolás-Fernandez F; Alunda JM
Int J Antimicrob Agents; 2007 Oct; 30(4):325-9. PubMed ID: 17631982
[TBL] [Abstract][Full Text] [Related]
16. Development and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasis.
Singodia D; Khare P; Dube A; Talegaonkar S; Khar RK; Mishra PR
J Biomed Nanotechnol; 2011 Feb; 7(1):123-4. PubMed ID: 21485834
[TBL] [Abstract][Full Text] [Related]
17. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.
Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR
Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628
[TBL] [Abstract][Full Text] [Related]
18. Development, characterization, and anti-leishmanial activity of topical amphotericin B nanoemulsions.
Dos Santos Matos AP; Lopes DCDXP; Peixoto MLH; da Silva Cardoso V; Vermelho AB; Santos-Oliveira R; Viçosa AL; Holandino C; Ricci-Júnior E
Drug Deliv Transl Res; 2020 Dec; 10(6):1552-1570. PubMed ID: 32676952
[TBL] [Abstract][Full Text] [Related]
19. Well-Tolerated Amphotericin B Derivatives That Effectively Treat Visceral Leishmaniasis.
Morelle C; Mukherjee A; Zhang J; Fani F; Khandelwal A; Gingras H; Trottier J; Barbier O; Leprohon P; Burke MD; Ouellette M
ACS Infect Dis; 2021 Aug; 7(8):2472-2482. PubMed ID: 34282886
[TBL] [Abstract][Full Text] [Related]
20. Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles.
Jain V; Gupta A; Pawar VK; Asthana S; Jaiswal AK; Dube A; Chourasia MK
Appl Biochem Biotechnol; 2014 Oct; 174(4):1309-1330. PubMed ID: 25106894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
